Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00245648 · ClinicalTrials.gov registry record · Phase 3
Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI
A Phase 3 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00245648: Completed Phase 3 study, sponsored by NYU Langone Health.
NCT00245648 is a Phase 3 study that has completed, run by NYU Langone Health. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00245648, a Phase 3 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
This study evaluated differences between men and women in the presentation, management and outcome of heart attacks within the GUSTO V study.
Primary Outcome
All cause mortality at 30 days after randomization.
Interventions
- DRUG fibrinolytic therapy or combination reduced fibrinolytic therapy
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-06 |
| Est. Completion | 2007-10 |
| Phase | Phase 3 |
What the finished NCT00245648 record still lists
NCT00245648 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which fibrinolytic therapy or combination reduced fibrinolytic therapy is the first listed.
NCT00245648 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00245648 about?
NCT00245648 is a clinical study titled "Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI". This study evaluated differences between men and women in the presentation, management and outcome of heart attacks within the GUSTO V study.
What is the current status of trial NCT00245648?
This trial is currently completed. It is a Phase 3 study. The study started on 2001-06. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00245648?
The interventions under investigation include: fibrinolytic therapy or combination reduced fibrinolytic therapy (DRUG).
Who is sponsoring clinical trial NCT00245648?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia